G3295

GW0742

≥98% (HPLC), selective PPARδ agonist, powder

• Synonym(e): 4-[2-(3-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]- 2-methyl-phenoxy}-acetic acid
• Empirische Formel (Hill-System): C₂₁H₁₇F₄NO₃S₂
• CAS-Nummer: 317318-84-6
• Molekulargewicht: 471.49
• UNSPSC Code: 12352200
• PubChem Substance ID: 24895123
• NACRES: NA.77
• MDL number: MFCD07369423
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: GW0742, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white
• mp: 134.5-135.5 °C
• solubility: DMSO: >5 mg/mL, H₂O: insoluble
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: Cc1cc(SCc2sc(nc2C)-c3ccc(c(F)c3)C(F)(F)F)ccc1OCC(O)=O
• InChI: 1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)
• InChI key: HWVNEWGKWRGSRK-UHFFFAOYSA-N
• Gene Information: human ... PPARA(5465), PPARD(5467), PPARG(5468)

Beschreibung

Biochem/physiol Actions

GW0742 is a highly selective PPARδ agonist.

GW0742 is a highly selective PPARδ agonist. EC₅₀ = 1 nM vs 1 μM and 2 μM for PPARα and PPARγ, respectively.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)